menu
    • menu
    [{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||5-LOX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for CAS-151767-02-1

    Menu

    CAS-151767-02-1

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IntelGenx Doses First Parkinson’s Patients with Montelukast VersaFilm in Phase 2 Trial

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2024

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IntelGenx Reports Preliminary Results for Montelukast VersaFilm® in Alzheimer’s Disease

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 07, 2024

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IntelGenx Receives Approval to Conduct MONTPARK™ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients ...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm for the...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 02, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Karolinska Institute

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IntelGenx

                            Canada arrow
                            Interphex
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Karolinska University Hospital

                            Deal Size : $2.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Pa...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 25, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Karolinska University Hospital

                            Deal Size : $2.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients wit...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 08, 2023

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Pa...

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2021

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

                            Details :

                            Product Name : Montelukast VersaFilm

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : Montelukast Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Novateur Ventures

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Novateur Ventures

                            Canada arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zileuton,Montelukast Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novateur Study Points Toward Potential COVID-19 Treatment

                            Details :

                            Product Name : Zyflo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 08, 2020

                            Lead Product(s) : Zileuton,Montelukast Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth